Novel domain-selective ACE-inhibiting activity of synthetic growth hormone secretagogues

Antonio Torsello, Elena Bresciani, Monica Ravelli, Laura Rizzi, Ilaria Bulgarelli, Giorgio Ricci, Barbara Ghiazza, Marina Del Puppo, Veronica Mainini, Robert J. Omeljaniuk, Laura Tamiazzo, Giuseppe Mancia, Fulvio Magni, Vittorio Locatelli

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The mechanisms of cardiovascular protective effects of ghrelin and its synthetic analogs are still largely unknown. Our first aim was to ascertain whether or not natural and synthetic ligands of GHS-R1a are capable of interfering with the activity of the renin-angiotensin system. Second, since polymorphisms in the ACE gene have been associated with Alzheimer's dementia (AD) and ACE is potentially involved in brain β-amyloid degradation, we also investigated the state of ghrelin axis and inflammatory markers in patients with AD and vascular dementia (VaD). Desacyl ghrelin, hexarelin, EP80317, and GHRP-6 all significantly inhibited ACE activity in vitro; by comparison, the efficacies of ghrelin and MK-0677 were significantly lower, suggesting that ACE-inhibiting activity is unrelated to ligand affinity to GHS-R1a. ACE was capable of cleaving Aβ in vitro, reducing its ability to aggregate in fibrillar Aβ. Interestingly, this protective effect of ACE was blunted by enalapril but not hexarelin or EP80317. Desacyl ghrelin levels were lower in VaD subjects compared with AD and control subjects, whereas ghrelin and TNF-α levels were similar in all groups. VaD subjects demonstrated greater levels of mRNA for GHS-R1a, PPAR-γ and CD36 in peripheral blood lymphocytes compared with other groups. In conclusion, some GHSs are effective ACE-inhibitors, and this activity may contribute to their cardiovascular effects. Hexarelin or EP80317 do not inhibit the N-domain of ACE, which is also involved in the metabolism of β-amyloid, suggesting the possibility of developing new antihypertensive drugs with improved therapeutic potential.

Original languageEnglish
Pages (from-to)317-324
Number of pages8
JournalPharmacological Research
Volume66
Issue number4
DOIs
Publication statusPublished - Oct 2012

Fingerprint

Ghrelin
Vascular Dementia
Growth Hormone
Alzheimer Disease
ibutamoren mesylate
Amyloid
Ligands
Peroxisome Proliferator-Activated Receptors
Enalapril
Aptitude
Renin-Angiotensin System
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Lymphocytes
Messenger RNA
Brain
Genes
hexarelin
EP80317
In Vitro Techniques

Keywords

  • β-Amyloid
  • ACE inhibitors
  • Alzheimer's dementia
  • EP80317
  • Ghrelin
  • Vascular dementia

ASJC Scopus subject areas

  • Pharmacology

Cite this

Torsello, A., Bresciani, E., Ravelli, M., Rizzi, L., Bulgarelli, I., Ricci, G., ... Locatelli, V. (2012). Novel domain-selective ACE-inhibiting activity of synthetic growth hormone secretagogues. Pharmacological Research, 66(4), 317-324. https://doi.org/10.1016/j.phrs.2012.06.006

Novel domain-selective ACE-inhibiting activity of synthetic growth hormone secretagogues. / Torsello, Antonio; Bresciani, Elena; Ravelli, Monica; Rizzi, Laura; Bulgarelli, Ilaria; Ricci, Giorgio; Ghiazza, Barbara; Del Puppo, Marina; Mainini, Veronica; Omeljaniuk, Robert J.; Tamiazzo, Laura; Mancia, Giuseppe; Magni, Fulvio; Locatelli, Vittorio.

In: Pharmacological Research, Vol. 66, No. 4, 10.2012, p. 317-324.

Research output: Contribution to journalArticle

Torsello, A, Bresciani, E, Ravelli, M, Rizzi, L, Bulgarelli, I, Ricci, G, Ghiazza, B, Del Puppo, M, Mainini, V, Omeljaniuk, RJ, Tamiazzo, L, Mancia, G, Magni, F & Locatelli, V 2012, 'Novel domain-selective ACE-inhibiting activity of synthetic growth hormone secretagogues', Pharmacological Research, vol. 66, no. 4, pp. 317-324. https://doi.org/10.1016/j.phrs.2012.06.006
Torsello, Antonio ; Bresciani, Elena ; Ravelli, Monica ; Rizzi, Laura ; Bulgarelli, Ilaria ; Ricci, Giorgio ; Ghiazza, Barbara ; Del Puppo, Marina ; Mainini, Veronica ; Omeljaniuk, Robert J. ; Tamiazzo, Laura ; Mancia, Giuseppe ; Magni, Fulvio ; Locatelli, Vittorio. / Novel domain-selective ACE-inhibiting activity of synthetic growth hormone secretagogues. In: Pharmacological Research. 2012 ; Vol. 66, No. 4. pp. 317-324.
@article{80a047b8dce041df9618038bee8db9b9,
title = "Novel domain-selective ACE-inhibiting activity of synthetic growth hormone secretagogues",
abstract = "The mechanisms of cardiovascular protective effects of ghrelin and its synthetic analogs are still largely unknown. Our first aim was to ascertain whether or not natural and synthetic ligands of GHS-R1a are capable of interfering with the activity of the renin-angiotensin system. Second, since polymorphisms in the ACE gene have been associated with Alzheimer's dementia (AD) and ACE is potentially involved in brain β-amyloid degradation, we also investigated the state of ghrelin axis and inflammatory markers in patients with AD and vascular dementia (VaD). Desacyl ghrelin, hexarelin, EP80317, and GHRP-6 all significantly inhibited ACE activity in vitro; by comparison, the efficacies of ghrelin and MK-0677 were significantly lower, suggesting that ACE-inhibiting activity is unrelated to ligand affinity to GHS-R1a. ACE was capable of cleaving Aβ in vitro, reducing its ability to aggregate in fibrillar Aβ. Interestingly, this protective effect of ACE was blunted by enalapril but not hexarelin or EP80317. Desacyl ghrelin levels were lower in VaD subjects compared with AD and control subjects, whereas ghrelin and TNF-α levels were similar in all groups. VaD subjects demonstrated greater levels of mRNA for GHS-R1a, PPAR-γ and CD36 in peripheral blood lymphocytes compared with other groups. In conclusion, some GHSs are effective ACE-inhibitors, and this activity may contribute to their cardiovascular effects. Hexarelin or EP80317 do not inhibit the N-domain of ACE, which is also involved in the metabolism of β-amyloid, suggesting the possibility of developing new antihypertensive drugs with improved therapeutic potential.",
keywords = "β-Amyloid, ACE inhibitors, Alzheimer's dementia, EP80317, Ghrelin, Vascular dementia",
author = "Antonio Torsello and Elena Bresciani and Monica Ravelli and Laura Rizzi and Ilaria Bulgarelli and Giorgio Ricci and Barbara Ghiazza and {Del Puppo}, Marina and Veronica Mainini and Omeljaniuk, {Robert J.} and Laura Tamiazzo and Giuseppe Mancia and Fulvio Magni and Vittorio Locatelli",
year = "2012",
month = "10",
doi = "10.1016/j.phrs.2012.06.006",
language = "English",
volume = "66",
pages = "317--324",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",
number = "4",

}

TY - JOUR

T1 - Novel domain-selective ACE-inhibiting activity of synthetic growth hormone secretagogues

AU - Torsello, Antonio

AU - Bresciani, Elena

AU - Ravelli, Monica

AU - Rizzi, Laura

AU - Bulgarelli, Ilaria

AU - Ricci, Giorgio

AU - Ghiazza, Barbara

AU - Del Puppo, Marina

AU - Mainini, Veronica

AU - Omeljaniuk, Robert J.

AU - Tamiazzo, Laura

AU - Mancia, Giuseppe

AU - Magni, Fulvio

AU - Locatelli, Vittorio

PY - 2012/10

Y1 - 2012/10

N2 - The mechanisms of cardiovascular protective effects of ghrelin and its synthetic analogs are still largely unknown. Our first aim was to ascertain whether or not natural and synthetic ligands of GHS-R1a are capable of interfering with the activity of the renin-angiotensin system. Second, since polymorphisms in the ACE gene have been associated with Alzheimer's dementia (AD) and ACE is potentially involved in brain β-amyloid degradation, we also investigated the state of ghrelin axis and inflammatory markers in patients with AD and vascular dementia (VaD). Desacyl ghrelin, hexarelin, EP80317, and GHRP-6 all significantly inhibited ACE activity in vitro; by comparison, the efficacies of ghrelin and MK-0677 were significantly lower, suggesting that ACE-inhibiting activity is unrelated to ligand affinity to GHS-R1a. ACE was capable of cleaving Aβ in vitro, reducing its ability to aggregate in fibrillar Aβ. Interestingly, this protective effect of ACE was blunted by enalapril but not hexarelin or EP80317. Desacyl ghrelin levels were lower in VaD subjects compared with AD and control subjects, whereas ghrelin and TNF-α levels were similar in all groups. VaD subjects demonstrated greater levels of mRNA for GHS-R1a, PPAR-γ and CD36 in peripheral blood lymphocytes compared with other groups. In conclusion, some GHSs are effective ACE-inhibitors, and this activity may contribute to their cardiovascular effects. Hexarelin or EP80317 do not inhibit the N-domain of ACE, which is also involved in the metabolism of β-amyloid, suggesting the possibility of developing new antihypertensive drugs with improved therapeutic potential.

AB - The mechanisms of cardiovascular protective effects of ghrelin and its synthetic analogs are still largely unknown. Our first aim was to ascertain whether or not natural and synthetic ligands of GHS-R1a are capable of interfering with the activity of the renin-angiotensin system. Second, since polymorphisms in the ACE gene have been associated with Alzheimer's dementia (AD) and ACE is potentially involved in brain β-amyloid degradation, we also investigated the state of ghrelin axis and inflammatory markers in patients with AD and vascular dementia (VaD). Desacyl ghrelin, hexarelin, EP80317, and GHRP-6 all significantly inhibited ACE activity in vitro; by comparison, the efficacies of ghrelin and MK-0677 were significantly lower, suggesting that ACE-inhibiting activity is unrelated to ligand affinity to GHS-R1a. ACE was capable of cleaving Aβ in vitro, reducing its ability to aggregate in fibrillar Aβ. Interestingly, this protective effect of ACE was blunted by enalapril but not hexarelin or EP80317. Desacyl ghrelin levels were lower in VaD subjects compared with AD and control subjects, whereas ghrelin and TNF-α levels were similar in all groups. VaD subjects demonstrated greater levels of mRNA for GHS-R1a, PPAR-γ and CD36 in peripheral blood lymphocytes compared with other groups. In conclusion, some GHSs are effective ACE-inhibitors, and this activity may contribute to their cardiovascular effects. Hexarelin or EP80317 do not inhibit the N-domain of ACE, which is also involved in the metabolism of β-amyloid, suggesting the possibility of developing new antihypertensive drugs with improved therapeutic potential.

KW - β-Amyloid

KW - ACE inhibitors

KW - Alzheimer's dementia

KW - EP80317

KW - Ghrelin

KW - Vascular dementia

UR - http://www.scopus.com/inward/record.url?scp=84864998047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864998047&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2012.06.006

DO - 10.1016/j.phrs.2012.06.006

M3 - Article

C2 - 22732396

AN - SCOPUS:84864998047

VL - 66

SP - 317

EP - 324

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 4

ER -